🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/06/2001 | 49,00 | 50,15 | 47,05 | 48,70 | -1,44% | 6,33% | 1.417.900 |
| 06/06/2001 | 50,89 | 50,90 | 48,15 | 49,41 | -3,06% | 5,40% | 1.535.000 |
| 05/06/2001 | 48,15 | 52,25 | 48,10 | 50,97 | +6,10% | 8,62% | 1.638.200 |
| 04/06/2001 | 44,53 | 48,25 | 44,50 | 48,04 | +8,13% | 8,42% | 1.307.600 |
| 01/06/2001 | 44,00 | 45,00 | 43,95 | 44,43 | +1,12% | 2,39% | 1.022.000 |
| 31/05/2001 | 42,84 | 44,80 | 42,81 | 43,94 | +3,63% | 4,65% | 1.770.400 |
| 30/05/2001 | 43,44 | 43,75 | 41,96 | 42,40 | -4,72% | 4,12% | 1.475.000 |
| 29/05/2001 | 45,25 | 46,10 | 44,25 | 44,50 | -2,09% | 4,09% | 1.158.500 |
| 25/05/2001 | 45,10 | 46,65 | 44,60 | 45,45 | +0,78% | 4,55% | 1.742.800 |
| 24/05/2001 | 42,10 | 45,25 | 41,35 | 45,10 | +7,20% | 9,26% | 1.399.500 |
| 23/05/2001 | 42,68 | 42,81 | 41,30 | 42,07 | -3,06% | 3,54% | 1.380.400 |
| 22/05/2001 | 42,21 | 43,50 | 40,52 | 43,40 | +4,00% | 7,06% | 2.083.000 |
| 21/05/2001 | 39,75 | 42,16 | 37,78 | 41,73 | +14,30% | 11,02% | 2.841.400 |
| 18/05/2001 | 37,76 | 37,77 | 35,30 | 36,51 | -1,06% | 6,54% | 1.028.200 |
| 17/05/2001 | 34,10 | 37,60 | 33,30 | 36,90 | +12,09% | 12,61% | 1.908.200 |
| 16/05/2001 | 31,00 | 34,04 | 30,80 | 32,92 | +4,54% | 10,45% | 1.452.600 |
| 15/05/2001 | 32,05 | 32,20 | 30,96 | 31,49 | -0,85% | 3,87% | 978.100 |
| 14/05/2001 | 32,65 | 32,70 | 31,36 | 31,76 | -2,99% | 4,10% | 1.096.600 |
| 11/05/2001 | 33,25 | 33,30 | 32,40 | 32,74 | -0,64% | 2,71% | 1.768.300 |
| 10/05/2001 | 36,38 | 36,51 | 32,44 | 32,95 | -5,83% | 11,19% | 1.294.400 |
| 09/05/2001 | 35,25 | 36,55 | 34,50 | 34,99 | -2,34% | 5,82% | 544.900 |
| 08/05/2001 | 37,22 | 37,29 | 35,00 | 35,83 | -1,10% | 6,15% | 1.009.200 |
| 07/05/2001 | 37,90 | 38,25 | 35,72 | 36,23 | -3,62% | 6,68% | 482.400 |
| 04/05/2001 | 34,75 | 37,60 | 33,56 | 37,59 | +6,40% | 11,63% | 1.086.300 |
| 03/05/2001 | 37,25 | 37,30 | 34,53 | 35,33 | -6,68% | 7,44% | 638.000 |
| 02/05/2001 | 37,97 | 38,98 | 36,92 | 37,86 | +1,07% | 5,43% | 864.800 |
| 01/05/2001 | 38,40 | 38,97 | 36,89 | 37,46 | -2,85% | 5,42% | 1.851.600 |
| 30/04/2001 | 36,94 | 39,34 | 35,97 | 38,56 | -1,76% | 9,12% | 3.920.500 |
| 27/04/2001 | 39,59 | 41,01 | 38,18 | 39,25 | -1,28% | 7,15% | 660.300 |
| 26/04/2001 | 39,44 | 40,25 | 37,05 | 39,76 | +2,61% | 8,11% | 1.120.900 |